A multicenter, cluster randomized controlled trial to investigate the effectiveness of the treatment guideline for major depressive disorder in Japan

A multicenter, cluster randomized controlled trial to investigate the effectiveness of the treatment guideline for major depressive disorder in Japan - A multicenter, cluster randomized controlled trial to investigate the effectiveness of the treatment guideline for major depressive disorder in Japan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034397

Enrollment

204

Registered

2019-01-01

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

The intervention will be carried out in one-day workshop. The training program consists of lectures (treatment guideline for major depressive disorder) and group education (social function, QOL, and s

treatment as usual&quot

(TAU) condition without the intervention.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the criteria for major depressive disorder according to DSM-5 and who are able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1) Severe depressive symptoms that require hospitalization 2) Having urgent suicidal ideation 3) Severe physical illness 4) Having dementia 5) Ongoing alcohol or substance abuse 6) Disturbance of consciousness

Design outcomes

Primary

Measure	Time frame
The primary outcome is the shared decision making scores at baseline, 4 weeks, and 12 weeks after enrollment in the study.	—

Secondary

Measure	Time frame
1) Client Satisfaction Questionnaire (CSQ-8-J) scores at baseline, 4 weeks, and 12 weeks 2) EuroQol 5 Dimension (EQ-5D) scores at baseline, 4 weeks, and 12 weeks 3) Trust in Physician Scale (TPS) scores at baseline, 4 weeks, and 12 weeks 4) Quick Inventory of Depressive Symptomatology (QIDS-J) scores at baseline, 4 weeks, and 12 weeks	—

Countries

Japan

Contacts

Public ContactYoshikazu Takaesu

Kyorin University Department of Neuropsychiatry, School of Medicine

takaesu@ks.kyorin-u.ac.jp0422-47-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026